Zim laboratories has witnessed a significant increase in shareholding by investor Mathew Cyriac and his associated entities. The group has raised their collective stake to 19.34% from the previous holding of 11.84%, marking a substantial 7.50% increase in ownership through strategic acquisitions completed in March 2026.

Transaction Overview

The acquisition involved multiple entities acting in concert with Mathew Cyriac, including Elimath Advisors Pvt Ltd, Elizabeth Mathew, and Florintree Trinex LLP. The transactions were executed through both open market purchases and preferential allotment, demonstrating a coordinated investment strategy.

Shareholding Changes by Entity

The disclosure reveals complex inter-group transactions among the persons acting in concert:

Mathew Cyriac (Individual):

• Sold 66,07,781 shares (12.35%)
• Acquired 18,15,957 shares (3.39%)
• Net position: Reduction in direct holding

Elimath Advisors Pvt Ltd:

• Sold 6,76,121 shares (1.26%)
• Acquired 56,16,150 shares (10.50%)
• Net position: Significant increase

Elizabeth Mathew:

• Acquired 54,35,824 shares (10.16%)
• Sold 63,35,824 shares (11.84%)
• Net position: Marginal reduction

Florintree Trinex LLP:

• Acquired 47,64,497 shares (8.91%) through preferential allotment

Current Holdings and Capital Structure

Following the transactions, the group's total shareholding stands at 1,03,48,766 shares, representing 19.34% of the company's equity capital. The company's equity share capital increased from 4,87,35,814 shares to 5,35,00,311 shares, with a face value of Rs. 10 per share.

Regulatory Compliance

The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as the group's total shareholding exceeded the threshold requiring public disclosure. The group clarified that they do not belong to the promoter or promoter group category.

ZIM Laboratories' shares are listed on both BSE Limited and National Stock Exchange of India Limited. The disclosure was filed on March 17, 2026, from Mumbai, maintaining compliance with regulatory timelines and requirements.

ZIM Laboratories announced the constitution of an Advisory Board on March 17, 2026, through a circular resolution passed by its Board of Directors. The pharmaceutical company established this advisory body to provide independent advice and strategic guidance on business development and related matters to the management and board.

Advisory Board Composition and Leadership

The newly formed Advisory Board consists of three distinguished industry professionals with extensive experience in healthcare, pharmaceuticals, and financial services:

Strategic Scope and Responsibilities

The Advisory Board will focus on several key areas to support ZIM Laboratories' growth objectives:

• Strategic Planning: Offering advice on long-term vision, mission, and growth strategy
• Business Development: Providing inputs on market expansion, new business lines, and brand strategy
• Industry Insights: Guidance on industry trends, competition analysis, and best practices
• Organizational Excellence: Advising on organizational structure and talent acquisition
• Governance: Supporting risk management and regulatory compliance initiatives

Leadership Profiles

Chairman - Mr. Annaswamy Vaidheesh

Mr. Vaidheesh brings nearly four decades of healthcare and MedTech leadership experience across Asia-Pacific and India. He currently serves as Chairman of Integris Medtech and Non-Executive Chairman of Appasamy Associates. His previous roles include Executive Chairman of Suven Pharmaceuticals, Managing Director of GSK Pharmaceuticals Ltd, and nearly three decades with Johnson & Johnson in various senior leadership positions across Asia-Pacific.

Member - Mr. Gautam Saigal

With over 35 years in financial services, Mr. Saigal has extensive experience in private equity investments, investment banking, and advisory services. He previously served as Managing Director of AA Indian Development Capital Advisors Private Limited and Associate Director of India Liaison Office of American International Group. He currently serves as Managing Partner of Pachira Financial Services LLP and holds board positions across multiple companies.

Member - Mr. Girdhar Balwani

Mr. Balwani is a seasoned pharmaceutical professional with over 40 years of experience across the Asia-Pacific region. His leadership experience includes serving as Managing Director of UCB Pharma (India) for seven years, Regional Director Asia Pacific with UCB Pharma for 10 years, and Managing Director of Menarini for five years. He has demonstrated expertise in sales, marketing, business development, and operations management.

Advisory Framework

The Advisory Board will operate purely in an advisory capacity to the Board of Directors, with no legal, fiduciary responsibilities, statutory authority, execution powers, or control over the company or its management. This structure allows the board to provide strategic guidance while maintaining clear governance boundaries.

About ZIM Laboratories

ZIM Laboratories Limited is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The company maintains state-of-the-art in-house R&D capabilities and offers innovative drug delivery solutions using proprietary technology platforms to enhance patient convenience and treatment adherence.